Cystinosis Community Statement October 2023 – Novartis Acquires AVROBIO
Dear Cystinosis Community, In May 2023, Novartis acquired the investigational autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis from AVROBIO. We look forward to continuing the development of this program and bringing new hope to patients with cystinosis. We thank you for your patience as we work quickly to transfer […]
Cystinosis Community Statement October 2023 – Novartis Acquires AVROBIO Read More »
